Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-03-01
2009-10-20
Helms, Larry R. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100
Reexamination Certificate
active
07604939
ABSTRACT:
The present invention provides screening methods for identifying BRM expression-promoting histone deacetylase (HDAC) inhibitors, diagnostic methods for determining the suitability of treatment of a candidate subject with a BRM expression-promoting HDAC inhibitor, and therapeutic methods for treating cancer cells in a patient with a BRM expression-promoting HDAC inhibitor. The present invention also provides BRG1 and BRM diagnostics, methods for increasing a cancer patient's resistance to viral infection, and methods for determining the suitability of treatment of a candidate subject with a glucocorticoid compound or retinoid compound.
REFERENCES:
patent: 5055608 (1991-10-01), Marks et al.
patent: 5175191 (1992-12-01), Marks et al.
patent: 5369108 (1994-11-01), Breslow et al.
patent: 5700811 (1997-12-01), Breslow et al.
patent: 5773474 (1998-06-01), Breslow et al.
patent: 5922837 (1999-07-01), Meinke et al.
patent: 5993845 (1999-11-01), Geerts et al.
patent: 6541661 (2003-04-01), Delorme et al.
patent: 6638530 (2003-10-01), Ishibashi et al.
patent: 6706686 (2004-03-01), Long et al.
patent: 6784173 (2004-08-01), Leser-Reiff et al.
patent: 6825317 (2004-11-01), Nishino et al.
patent: 2002/0103192 (2002-08-01), Curtin et al.
patent: 2002/0177594 (2002-11-01), Curtin et al.
patent: 2003/0013757 (2003-01-01), Leser-Reiff et al.
patent: 2003/0129724 (2003-07-01), Grozinger et al.
patent: 2003/0206946 (2003-11-01), Chung
patent: 2004/0077698 (2004-04-01), Georges et al.
patent: 2004/0132825 (2004-07-01), Bacopoulos et al.
patent: 2004/0214860 (2004-10-01), Charous et al.
patent: 2004/0224991 (2004-11-01), Lu et al.
patent: 2004/0229889 (2004-11-01), Urano et al.
patent: 2005/0032831 (2005-02-01), Kozikowski et al.
patent: 1426054 (2002-08-01), None
patent: WO 01/18171 (2001-03-01), None
patent: WO0215921 (2002-02-01), None
patent: WO2004046094 (2004-06-01), None
patent: WO2004113336 (2004-12-01), None
Yamamichi-Nishina et al. (JBC, vol. 278(9), pp. 7422-7430, Feb. 2003.
Wang et al., “he SWI/SNF family of ATP-dependent chromatin remodelers: similar mechanisms for diverse functions,” Curr. Top. Microbiol. Immunol., 2003, 274:143-69.
Reisman et al., “Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression.,” Oncogene, 2002, 21(8):1196-207.
Reisman et al., “Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis,” Cancer Res., 2003, 63(3), 560-6.
Yoshida et al., “Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function,” Bioassays 17, 423-430 (1995).
Saito et al., “A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors,” PNAS USA 96, 4592-4597, (1999).
Furamai et al., “Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.,” PNAS USA 98 (1), 87-92 (2001).
Komatsu et al., “Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.,” Cancer Res. 61(11), 4459-4466 (2001).
Lee et al., “MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells,” Cancer Res. 61(3), 931-934 (2201).
Suzuki et al., “Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives,” J. Med. Chem. 42(15), 3001-3003 (1999).
Bourachot et al., “Growth inhibition by the mammalian SWI-SNF subunit Brm is regulated by acetylation,” EMBO (2003) 24 pg. 6505-6515.
Qian et al., “argeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589,” Clin. Cancer. Res., 2006, 12(2):634-42.
Remiszewski et al., “N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3[4-[[(2-hydroxyethyl)[2-(1H-Indol-3-yl)ethyl]amino] methyl]phenyl]-2-propenamide (NVP-LAQ824).,” J. Med. Chem., 2003, 46(21):4609-24.
Schroeder and Neagle, “FLIPR: A New Instrument for Accurate, High Trhoughput Optical Screening,” J. Biomol. Screening 1:75 [1996].
Glaser et al., “Role of class I and class II histone deacetylases in carcinoma cells using siRNA.,” Biochemical and Biophysical Res. Comm., 310:529-36, 2003.
Wong et al., “BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines.,” Cancer Res. 60:6171-6177, 2000.
Miller et al., “Induction of a high incidence of lung tumors in C57BL/6 mice with multiple ethyl carbamate injections,” Cancer Lett, 198:139-144, 2003.
Yamamichi et al., “The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potentia,” Oncogene (2005) 1-11.
Su et al. “A Novel Histone Deacetylase Inhibitor Identified by High-Throughput Transcriptional Screening of a Compound Library,” Cancer Res 60 (12): 3137 (2000).
Bourachot et al. Growth inhibition by the mammalian SWI-SNF subunit Brm is regulated by acetylation. The EMBO Journal. 2003. vol. 22, No. 24; p. 6505-6515.
Yamamichi-Nishina et al. SW13 cells can transition between two distinct subtypes by switching expression of BFG1 and Brm genes at the post-transcription level. J of Biological Chemistry. Feb. 2003. vol. 278, No. 9; p. 7422-7430.
Mizutani et al. Maintenance of integrated proviral gene expression requires Brm, a catalytic subunit of SWI/SNF complex. J of Biological Chemistry. May 2002. vol. 277, No. 18; p. 15859-15864.
Wong et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Research. Nov. 2000. vol. 60; p. 6171-6177.
Reisman et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines; differential effects on RB-mediated growth arrest vs. CD44 expression. Oncogene. 2002. vol. 21; p. 1196-1207.
Casimir Jones SC
Helms Larry R.
Natarajan Meera
The Regents of the University of Michigan
LandOfFree
Methods of identifying active BRM expression-promoting HDAC... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of identifying active BRM expression-promoting HDAC..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of identifying active BRM expression-promoting HDAC... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084712